Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Amgen's change in inventory for the quarter that ended in Jun. 2026 was R$-159 Mil. It means Amgen's inventory
increased by R$159 Mil
from Mar. 2026 to Jun. 2026 .
Amgen's change in inventory for the fiscal year that ended in Dec. 2025 was R$4,834 Mil. It means Amgen's inventory
declined by R$4,834 Mil
from Dec. 2024 to Dec. 2025 .
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Amgen's Days Inventory for the quarter that ended in Jun. 2026 was 203.43.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Amgen's Inventory Turnover for the quarter that ended in Jun. 2026 was 0.45.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Amgen's Inventory-to-Revenue for the quarter that ended in Jun. 2026 was 0.62.
3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Amgen's Inventory to Revenue for the quarter that ended in Jun. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amgen Change In Inventory Related Terms
Amgen Change In Inventory Historical Data
* Premium members only.
The historical data trend for Amgen's Change In Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.
Change In Inventory for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$1,872 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Change In Inventory of R$1,872 Mil mean?
Amgen (BSP:AMGN34) has a Change In Inventory of R$1,872 Mil as of Jun. 2026. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Amgen and its competitors.
Is Amgen's Change In Inventory too high?
Amgen's current Change In Inventory is R$1,872 Mil. Overall, Amgen has a GF Score™ of 89/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Amgen's Change In Inventory compare to GILD and PFE?
Amgen's Change In Inventory of R$1,872 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Inventory for a Drug Manufacturers company?
A good Change In Inventory depends on the Drug Manufacturers industry context. However, Change In Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Inventory mean?
A high Change In Inventory can signal that a stock is expensive relative to its fundamentals. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Amgen and its competitors. Amgen's current Change In Inventory is R$1,872 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amgen stock overvalued right now?
Based on GuruFocus' analysis, Amgen (BSP:AMGN34) is currently considered Modestly Overvalued. The stock's GF Value™ is R$65.67, compared to a current price of R$79.54 — trading 21.1% above its estimated fair value. The current Change In Inventory is R$1,872 Mil. Amgen's overall GF Score™ is 89/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Inventory calculated?
Change In Inventory is calculated from a company's financial statements. For Amgen (BSP:AMGN34), the current Change In Inventory is R$1,872 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Amgen (BSP:AMGN34) Overvalued in 2026?
Based on GuruFocus' analysis, Amgen stock appears to be overvalued.
The current stock price of R$79.54 is trading 21.1% above its estimated GF Value™ of R$65.67.
GuruFocus considers Amgen to be Modestly Overvalued.
Key valuation signals for BSP:AMGN34:
Change In Inventory: R$1,872 Mil
GF Value™: R$65.67 vs. price of R$79.54 (21.1% above fair value)
No single metric tells the full story. See the BSP:AMGN34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
89GF Score
Get the complete analysis for BSP:AMGN34
Change In Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:AMGN34 has been successfully added to your 
